Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Reviva Pharmaceuticals Holdings (RVPH) Stock Price & Analysis

1,273 Followers

RVPH Stock Chart & Stats

$0.39$0.05(14.12%)
At close: 4:00 PM EST
$0.35$0.4$0.45$0.5Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$0.34 - $0.41
52-Week Range
$0.26 - $15.42
Previous Close
$0.34
Volume
N/A
Average Volume (3M)
35.21K
Market Cap
$4.46M
Enterprise Value
-$11.44M
Total Cash (Recent Filing)
$17.46T
Total Debt (Recent Filing)
$44.39B
Price to Earnings (P/E)
―
Beta
1.61
Next Earnings
Apr 05, 2027 (Est.)
EPS Estimate
-0.28
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Lead CNS Drug Program

Brilaroxazine gives Reviva a defined lead asset and a focused development path in schizophrenia and related neuropsychiatric disorders. Progress in this program could create a commercial foundation and establish meaningful product value if clinical development and regulatory objectives are achieved.

Diversified Therapeutic Focus

Activity across CNS, inflammatory, and cardiometabolic diseases provides more than one potential therapeutic avenue and reduces reliance on a single disease category. A broader pipeline can preserve strategic options and support future value creation if additional programs advance successfully.

Modest Leverage

Low debt relative to equity reduces immediate balance-sheet pressure and limits the burden of interest or mandatory debt service. This gives management somewhat greater flexibility to direct available resources toward research and development while pursuing the company’s clinical pipeline.

Bears Say

Pre-Revenue Loss Profile

The absence of revenue and persistence of large operating and net losses show that the business has not yet reached a commercial earnings base. Until a program is approved and monetized, financial performance remains dependent on clinical progress rather than recurring operating revenue.

Persistent Cash Burn

Consistently negative operating and free cash flow means Reviva must continue funding research and corporate activities without internally generated cash. This can increase reliance on external financing, potentially constrain development choices and create ongoing dilution or funding pressure.

Volatile TTM Financial Results

The sharp deterioration in TTM cash outflow and losses versus recent annual periods makes the current funding requirement harder to forecast. Greater volatility can complicate capital planning, increase uncertainty around runway, and weaken confidence in the sustainability of the historical cost profile.

Reviva Pharmaceuticals Holdings News

RVPH FAQ

What was Reviva Pharmaceuticals Holdings’s price range in the past 12 months?
Reviva Pharmaceuticals Holdings lowest stock price was $0.26 and its highest was $15.42 in the past 12 months.
What is Reviva Pharmaceuticals Holdings’s market cap?
Reviva Pharmaceuticals Holdings’s market cap is $4.46M.
When is Reviva Pharmaceuticals Holdings’s upcoming earnings report date?
Reviva Pharmaceuticals Holdings’s next earnings report is estimated for Apr 05, 2027 (not yet confirmed), which is in 143 days.
How were Reviva Pharmaceuticals Holdings’s earnings last quarter?
Reviva Pharmaceuticals Holdings released its earnings results on Nov 13, 2026. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.29 by $0.12.
Is Reviva Pharmaceuticals Holdings overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Reviva Pharmaceuticals Holdings pay dividends?
Reviva Pharmaceuticals Holdings does not currently pay dividends.
What is Reviva Pharmaceuticals Holdings’s EPS estimate?
Reviva Pharmaceuticals Holdings’s EPS estimate is -0.28.
How many shares outstanding does Reviva Pharmaceuticals Holdings have?
Reviva Pharmaceuticals Holdings has 13,110,377 shares outstanding.
What happened to Reviva Pharmaceuticals Holdings’s price movement after its last earnings report?
Reviva Pharmaceuticals Holdings reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.29. Following the earnings report the stock price went up 9.565%.
Which hedge fund is a major shareholder of Reviva Pharmaceuticals Holdings?
Hedge funds hold Reviva Pharmaceuticals Holdings shares: the largest hedge-fund position in Reviva Pharmaceuticals Holdings is 71,888,555 shares, and hedge funds decreased their holdings by 780.8K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology